Overactive Bladder

Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms - Abstract

Published on Thursday, 04 April 2013 14:46

Background: Patients' treatment goals for overactive bladder (OAB) and other lower urinary tract symptoms (LUTS) may not be aligned with their healthcare provider's goals.

Results of a randomised phase III trial assessing the tolerability and efficacy of mirabegron for the treatment of OAB, "Beyond the Abstract," by Vik Khullar BSc, MD, FRCOG, AKC and Rhiannon Bray, MD

Published on Wednesday, 03 April 2013 12:21

BERKELEY, CA (UroToday.com) - Oral pharmacological treatment options for overactive bladder (OAB) include antimuscarinics as first-line therapy.^[1,2]

A Population-based survey of lower urinary tract symptoms (LUTS) and symptom-specific bother: Results from the Brazilian LUTS epidemiology study (BLUES) - Abstract

Published on Wednesday, 03 April 2013 09:31

PURPOSE: To examine the prevalence of lower urinary tract symptoms (LUTS) and the bother they impose in a population-based sample of adults in Brazil.

A pelvic floor fitness program for older women with urinary symptoms: A feasibility study - Abstract

Published on Tuesday, 02 April 2013 07:16

OBJECTIVE: To determine the feasibility of an adapted pelvic fitness and educational program to control urinary incontinence (UI) and overactive bladder (OAB) symptoms in women over 65 years of age.

Increasing patient preparedness for sacral neuromodulation improves patient-reported outcomes despite leaving objective measures of success unchanged - Abstract

Published on Monday, 01 April 2013 09:23

INTRODUCTION: We assessed how a GSA influenced patient preparedness for, as well as both subjective and objective outcomes of SNS for refractory overactive bladder and/or urge urinary incontinence.

Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: A single-dose, randomized, crossover study in healthy adults - Abstract

Published on Friday, 29 March 2013 08:52

BACKGROUND: Mirabegron is a β₃-adrenoceptor agonist used for the treatment of overactive bladder.

Practical use of the new American Urological Association Adult Urodynamics Guidelines - Abstract

Published on Thursday, 28 March 2013 15:58

In 2012, the American Urological Association published guidelines on adult urodynamics.

Synergistic effect of iontophoresis and chemical enhancers on transdermal permeation of tolterodine tartrate for the treatment of overactive bladder - Abstract

Published on Wednesday, 27 March 2013 13:25

Purpose: The objective of the study was to evaluate the synergistic transdermal permeation effect of chemical enhancers and iontophoresis technique on tolterodine tartrate (TT) transdermal gel and to evaluate its pharmacokinetic properties.

Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome - Abstract

Published on Tuesday, 26 March 2013 07:08

AIMS: To analyze the predictors of therapeutic success after solifenacin treatment.

Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: Does using onabotulinumtoxinA (Botox® ) or abobotulinumtoxinA (Dysport® ) make a difference? - Abstract

Published on Monday, 25 March 2013 17:15

OBJECTIVE: To compare the clinical effects of two different commercially available botulinum toxin type A products, onabotulinumtoxinA (Botox® ; Allergan Inc., Irvine, CA, USA) and abobotulinumtoxinA (Dysport® ; Ipsen Ltd, Slough, UK), on non-neurogenic overactive bladder (OAB).

Page 5 of 54